649 A Randomized Placebo-Controlled Trial of Abatacept for Moderately-to-Severely Active Crohn's Disease (CD)
Stephen B. Hanauer(Northwestern University), Allison Luo(Merck & Co., Inc., Rahway, NJ, USA (United States)), William J. Sandborn(University of San Diego), René Swanink, Brian Bressler(University of British Columbia), Marvilyn A. Whiteside, Paul Rutgeerts(KU Leuven), Remo Panaccione(University of Calgary), Richard Aranda(Bristol-Myers Squibb (Germany)), Bruce E. Sands(Icahn School of Medicine at Mount Sinai)
Cited by 11
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k